Anti-Human IGF1 Receptor Therapeutic Antibody (Cixutumumab)

Recombinant monoclonal antibody to IGF1 Receptor. Cixutumumab is a monoclonal antibody for the treatment of solid tumors.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
Supplier Creative Biolabs
Product # TAB-078
Pricing Inquiry
Host Human
Target IGF1 Receptor
Species Reactivity Human
Type IgG1 - lambda
Applications IP, Neut, FuncS, ELISA, FC, WB, IHC, Stim, IF, Block
Storage Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
Feedback